Amorphical is a pioneering Israeli pharmaceutical company developing and manufacturing a proprietary synthetic form of calcium, Amorphous Calcium Carbonate (ACC). Our ACC-based therapeutics are in clinical development for the treatment of osteoporosis, hypoparathyroidism and a wide range of other calcium-related diseases. This novel technology is protected by several approved and pending patents.
Inspired by the natural ability of the Australian Blue Crayfish to efficiently mobilize its calcium stores in order to shed and regrow its entire exoskeleton in only three days, Amorphical scientists have shown ACC’s safety and efficacy in preclinical studies.* Moreover, the company has demonstrated ACC's high bioavailability (twice that of conventional crystalline calcium carbonate, CCC) in a double-blind, randomized, crossover study in post-menopausal women.*
DENSITY, Amorphical's first ACC-based product, is a food supplement which has been approved for over-the-counter sale and distribution by both Israel's Ministry of Health and Hong Kong’s Centre of Food Safety. Thousands of people now use DENSITY as an everyday calcium supplement.
The company’s R&D pipeline continues to expand and currently includes clinical trials of ACC-based products for the treatment of osteoporosis, hypoparathyroidism, and cancer-related bone metastasis.